103412-68-6

Basic information

• Product Name: 1H-1-BENZAZEPINE 1- ACETIC ACID, 3-AMINO-2,3,4,5-TETRAHYDRO-2-OXO PHENYL METHYL ESTER (+ )
• Synonyms: 1H-1-BENZAZEPINE 1- ACETIC ACID, 3-AMINO-2,3,4,5-TETRAHYDRO-2-OXO PHENYL METHYL ESTER (+ )
• CAS NO: 103412-68-6
• Molecular Formula: MW:
• Molecular Weight: 0
• Mol File: 103412-68-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-1-BENZAZEPINE 1- ACETIC ACID, 3-AMINO-2,3,4,5-TETRAHYDRO-2-OXO PHENYL METHYL ESTER (+ )(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1-BENZAZEPINE 1- ACETIC ACID, 3-AMINO-2,3,4,5-TETRAHYDRO-2-OXO PHENYL METHYL ESTER (+ )(103412-68-6)
• EPA Substance Registry System: 1H-1-BENZAZEPINE 1- ACETIC ACID, 3-AMINO-2,3,4,5-TETRAHYDRO-2-OXO PHENYL METHYL ESTER (+ )(103412-68-6)

Safety Data

• Hazardous Substances Data: 103412-68-6(Hazardous Substances Data)

Usage

Family

1-benzazepine

Family

The compound belongs to the 1-benzazepine family, which is a group of organic compounds that have a benzene ring fused to a seven-membered nitrogen-containing ring.

Contains

a phenyl methyl ester group

Contains

The compound contains a phenyl methyl ester group, which is a functional group that consists of a phenyl ring attached to a carbonyl group, which is in turn attached to a methyl group.

Use

in medical research and pharmaceutical development as a potential therapeutic agent

Use

The compound is used in medical research and pharmaceutical development as a potential therapeutic agent. This means that it is being studied for its potential to be used as a drug to treat certain medical conditions.

Safety

important to handle with care and follow safety precautions in a laboratory setting

Safety

It is important to handle this chemical with care and to follow safety precautions when working with it in a laboratory setting. This is because it is an organic compound that may have hazardous properties, such as being flammable or toxic.

Upstream product

• 1634-04-4 tert-butyl methyl ether 
• 497-19-8 sodium carbonate 
• 98626-45-0 1-tert-butoxycarbonylmethyl-3S-amino-2,3,4,5-tetrahydro-1H-⁽¹⁾-benzazepin-2-one 
• 86499-35-6 3-amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 5437-45-6 Benzyl bromoacetate 
• 156247-61-9 (S)-tert-butyl (2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)carbamate 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 3349-64-2 1-tetralone oxime 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 368426-46-4 (3-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-acetic acid benzyl ester 

Downstream Products

• 86541-74-4 benazepril hydrochloride 

Relevant articles and documents

Novel, potent non-covalent thrombin inhibitors incorporating P3-lactam scaffolds

Evolution of P1-argininal inhibitor prototypes led to a series of non-covalent P3-7-membered lactam inhibitors 1a-w, featuring novel peptidomimetic units that probe each of the S1, S2, and S3 specificity pockets of thrombin. Rigid P1-arginine surrogates possessing a wide range of basicity (calcd pKa's～neutral-14) were surveyed. The design, synthesis, and biological activity of these targets are presented.

Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives process for their preparation and pharmaceutical compositions comprising them

Compounds having NEP-inhibitory activity, corresponding to the formula I in whichR 1 is hydrogen or a group forming a biolabile phosphonic acid ester,R 2 is hydrogen or a group forming a biolabile phosphonic acid ester and R. sup.3 is hydrogen or a group forming a biolabile carboxylic acid esterand physiologically acceptable salts of acids of formula I, and pharmaceutical compositions comprising these compounds.

Pharmaceuticals which promote gastrointestinal blood circulation

The use is described of compounds of the general formula I STR1 wherein R1 represents a phenyl-lower alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or represents a naphthyl-lower alkyl group, R2 denotes hydrogen or a biolabile ester-forming group, and R3 denotes hydrogen or a biolabile ester-forming group, and physiologically acceptable salts of the acids of formula I for preparing pharmaceutical compositions for the treatment and/or prophylaxis of gastrointestinal blood circulation disturbances.

BENZAZEPINE-, BENZOXAZEPINE- AND BENZOTHIAZEPINE-N-ACETIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds with neutral endopeptidase (NEP) inhibitory activity corresponding to the formula I STR1 in which R 1 is a lower alkoxy-lower-alkyl group whose lower alkoxy radical is substituted by a lower alkoxy group, or a phenyl-lower-alkyl or phenyloxy-lower-alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or a naphthyl-lower-alkyl group, A is CH 2, O or S,R 2 is hydrogen or halogen,R. sup.3 is hydrogen or halogen,R 4 is hydrogen or a group forming a biolabile ester, andR 5 is hydrogen or a group forming a biolabile ester, and the physiologically acceptable acid addition salts thereof.

3-Amino-[1]-benzazepin-2-one-1-alkanoic acids

Variously substituted 1-carboxymethyl-3-(carboxymethylamino)-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-ones and functional derivatives are angiotensin converting enzyme inhibitors and are useful as antihypertensive agents. Synthesis of, compositions and methods of treatment utilizing such compounds are included.

3-Amino-[1]-benzazepin-2-one-1-alkanoic acids

Variously substituted 1-carboxymethyl-3-(carboxymethylamino)-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-ones and functional derivatives are angiotension converting enzyme inhibitors and are useful as antihypertensive agents. Synthesis of, compositions and methods of treatment utilizing such compounds are included.